Shopping Cart 0
Cart Subtotal
AED 0

Antibe Therapeutics Inc (ATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 0

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 0

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 0

Details

Summary

Antibe Therapeutics Inc (Antibe) is a biotech company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercializes novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen derivative for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis; ATB-352 for gout, dental pain, post-surgical pain, and ATB-340 for chronic prevention of cardiovascular disease and cancer chemoprevention. Antibe also offers regenerative medical devices such as CGX-227, CGX-443 and CGX-276 which are indicated for oral and maxillofacial surgery. The company markets its products in Canada and abroad. Antibe is headquartered in Toronto, Ontario, Canada.

Antibe Therapeutics Inc (ATE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Licensing Agreements 12

Kwang Dong Pharma Enters into Licensing Agreement with Antibe Therapeutics 12

Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 13

Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 14

Equity Offering 15

Antibe Therapeutics Raises USD2.38 Million in Private Placement of Common Shares 15

Antibe Therapeutics Raises USD0.7 Million in Second Tranche Public Offering of Units 16

Antibe Therapeutics Raises USD3 Million in Public Offering of Units 18

Antibe Therapeutics Raises USD2 Million in Private Placement of Units 20

Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 21

Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 22

Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 24

Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 3.5 Million 25

Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For USD 1.2 Million 26

Antibe Therapeutics Completes IPO For USD 3 Million 27

Antibe Therapeutics Completes Private Placement Of Common Stock For USD 0.2 Million 29

Debt Offering 30

Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 30

Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 31

Antibe Therapeutics Inc-Key Competitors 32

Antibe Therapeutics Inc-Key Employees 33

Antibe Therapeutics Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 35

Financial Announcements 35

Jun 29, 2018: Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results 35

Nov 28, 2017: Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update 36

Aug 29, 2017: Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results 37

Mar 01, 2017: Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results 38

Corporate Communications 39

Oct 22, 2018: Antibe Therapeutics establishes business development Advisory Board 39

Product News 40

May 24, 2018: Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology 40

Clinical Trials 41

Apr 26, 2017: Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic 41

Other Significant Developments 42

Apr 03, 2018: Antibe Therapeutics Provides Financial Update 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Antibe Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Kwang Dong Pharma Enters into Licensing Agreement with Antibe Therapeutics 12

Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 13

Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 14

Antibe Therapeutics Raises USD2.38 Million in Private Placement of Common Shares 15

Antibe Therapeutics Raises USD0.7 Million in Second Tranche Public Offering of Units 16

Antibe Therapeutics Raises USD3 Million in Public Offering of Units 18

Antibe Therapeutics Raises USD2 Million in Private Placement of Units 20

Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 21

Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 22

Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 24

Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 3.5 Million 25

Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For USD 1.2 Million 26

Antibe Therapeutics Completes IPO For USD 3 Million 27

Antibe Therapeutics Completes Private Placement Of Common Stock For USD 0.2 Million 29

Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 30

Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 31

Antibe Therapeutics Inc, Key Competitors 32

Antibe Therapeutics Inc, Key Employees 33

Antibe Therapeutics Inc, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Antibe Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Antibe Therapeutics Inc (Antibe) is a biotech company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercializes novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen derivative for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis; ATB-352 for gout, dental pain, post-surgical pain, and ATB-340 for chronic prevention of cardiovascular disease and cancer chemoprevention. Antibe also offers regenerative medical devices such as CGX-227, CGX-443 and CGX-276 which are indicated for oral and maxillofacial surgery. The company markets its products in Canada and abroad. Antibe is headquartered in Toronto, Ontario, Canada.

Antibe Therapeutics Inc (ATE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Licensing Agreements 12

Kwang Dong Pharma Enters into Licensing Agreement with Antibe Therapeutics 12

Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 13

Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 14

Equity Offering 15

Antibe Therapeutics Raises USD2.38 Million in Private Placement of Common Shares 15

Antibe Therapeutics Raises USD0.7 Million in Second Tranche Public Offering of Units 16

Antibe Therapeutics Raises USD3 Million in Public Offering of Units 18

Antibe Therapeutics Raises USD2 Million in Private Placement of Units 20

Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 21

Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 22

Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 24

Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 3.5 Million 25

Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For USD 1.2 Million 26

Antibe Therapeutics Completes IPO For USD 3 Million 27

Antibe Therapeutics Completes Private Placement Of Common Stock For USD 0.2 Million 29

Debt Offering 30

Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 30

Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 31

Antibe Therapeutics Inc-Key Competitors 32

Antibe Therapeutics Inc-Key Employees 33

Antibe Therapeutics Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 35

Financial Announcements 35

Jun 29, 2018: Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results 35

Nov 28, 2017: Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update 36

Aug 29, 2017: Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results 37

Mar 01, 2017: Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results 38

Corporate Communications 39

Oct 22, 2018: Antibe Therapeutics establishes business development Advisory Board 39

Product News 40

May 24, 2018: Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology 40

Clinical Trials 41

Apr 26, 2017: Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic 41

Other Significant Developments 42

Apr 03, 2018: Antibe Therapeutics Provides Financial Update 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Antibe Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Kwang Dong Pharma Enters into Licensing Agreement with Antibe Therapeutics 12

Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 13

Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 14

Antibe Therapeutics Raises USD2.38 Million in Private Placement of Common Shares 15

Antibe Therapeutics Raises USD0.7 Million in Second Tranche Public Offering of Units 16

Antibe Therapeutics Raises USD3 Million in Public Offering of Units 18

Antibe Therapeutics Raises USD2 Million in Private Placement of Units 20

Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 21

Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 22

Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 24

Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 3.5 Million 25

Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For USD 1.2 Million 26

Antibe Therapeutics Completes IPO For USD 3 Million 27

Antibe Therapeutics Completes Private Placement Of Common Stock For USD 0.2 Million 29

Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 30

Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 31

Antibe Therapeutics Inc, Key Competitors 32

Antibe Therapeutics Inc, Key Employees 33

Antibe Therapeutics Inc, Subsidiaries 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Antibe Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.